ClinicalTrials.gg
RecruitingNCT07235059Updated Nov 10, 2026

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease

A Phase 1 interventional study of OJR520 and Placebo in Chronic Kidney Disease, sponsored by Novartis Pharmaceuticals. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Renal Insufficiency, Chronic by Novartis — 4 open to participants now, 6 under way, 5 of them phase 3. Renal Insufficiency, Chronic · Novartis.

Planned enrollment
17th of 26
112 · median 147
Started
2025
with 1 other
Phase 1
3 of 28
1 open now
Registered
27th of 28
by date

Among the 28 studies in Renal Insufficiency, Chronic by Novartis, this one is the 17th largest by planned enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2025, is one of 3 in phase 1, and was the 27th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

4 of the 28 studies in Renal Insufficiency, Chronic by Novartis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Renal Insufficiency, Chronic by Novartis, or all of them as a file.
02

Study summary

The purpose of this first-in-human (FIH) study is to evaluate safety, tolerability, pharmacokinetic (PK) of OJR520.

Read the detailed description

This is a three-part randomized, participant- and investigator blinded, placebo-controlled, multi-center, sequential study: single ascending dose (SAD) in healthy volunteers (HV), SAD in participants with chronic kidney disease (CKD) or diabetic chronic kidney disease (DKD) and multiple ascending dose (MAD) in participants with CKD or DKD.

03

Conditions studied

  • Chronic Kidney Disease

Keywords

  • OJR520
  • safety and tolerability
  • PK
  • PD
  • healthy volunteers
  • first in human
  • chronic kidney disease
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Able to provide written before any assessment is performed.

Part A (HV):

  • Healthy male and female participants in good health as determined by past medical history, physical examination, vital signs, 12-lead , and laboratory tests at screening and baseline within the normal range.

Parts B \& C (CKD)

  • Male and female participants 18 to 65 years of age.

Exclusion criteria

Exclusion Criteria:

  • Women of .
  • Sexually active males unwilling to use .

Part A (HV):

  • abnormal blood pressure, defined as SBP \<90 mmHg or >140 mmHg or DBP \<55 mmHg or >95 mmHg.
  • Abnormal resting HR, defined as \<45 bpm or >90 bpm.

Part B \& C (CKD)

  • History of, or currently active, significant illness or medical disorders including, but not limited to, cancer (except for non-melanoma skin cancer), heart failure III-IV, heart rhythm abnormalities (e.g., atrial fibrillation, sick sinus syndrome, permanent pacemaker), CKD due to disease, kidney transplant, dialysis or any other disease the investigator believes may preclude the participant from participating in the this study.
  • Clinically significant aortic stenosis or mitral insufficiency as identified via echocardiography.
  • History of myocardial infarction (MI), stroke, coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), or (TIA).

Other protocol defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
112 participants (estimated)

Study arms

  • Experimental
    Part A: OJR520 dose A1

    Participants will receive OJR520 dose level A1.

    Drug: OJR520

  • Experimental
    Part A: OJR520 dose A2

    Participants will receive OJR520 dose level A2.

    Drug: OJR520

  • Experimental
    Part A: OJR520 dose A3

    Participants will receive OJR520 dose level A3.

    Drug: OJR520

  • Experimental
    Part A: OJR520 dose A4

    Participants will receive OJR520 dose level A4.

    Drug: OJR520

  • Experimental
    Part A: OJR520 dose A5

    Participants will receive OJR520 dose level A5.

    Drug: OJR520

  • Experimental
    Part A: OJR520 dose A6

    Participants will receive OJR520 dose level A6.

    Drug: OJR520

  • Experimental
    Part B: OJR520 dose B1

    Participants will receive OJR520 dose level B1.

    Drug: OJR520

  • Experimental
    Part B: OJR520 dose B2

    Participants will receive OJR520 dose level B2.

    Drug: OJR520

  • Experimental
    Part B: OJR520 dose B3

    Participants will receive OJR520 dose level B3.

    Drug: OJR520

  • Experimental
    Part B: OJR520 dose B4

    Participants will receive OJR520 dose level B4.

    Drug: OJR520

  • Experimental
    Part C: OJR520 dose C1

    Participants will receive OJR520 dose level C1.

    Drug: OJR520

  • Experimental
    Part C: OJR520 dose C2

    Participants will receive OJR520 dose level C2.

    Drug: OJR520

  • Experimental
    Part C: OJR520 dose C3

    Participants will receive OJR520 dose level C3.

    Drug: OJR520

  • Experimental
    Part C: OJR520 dose C4

    Participants will receive OJR520 dose level C4.

    Drug: OJR520

  • Placebo comparator
    Part A: Placebo

    Participants will receive the matching placebo.

    Other: Placebo

  • Placebo comparator
    Part B: Placebo

    Participants will receive the matching placebo.

    Other: Placebo

  • Placebo comparator
    Part C: Placebo

    Participants will receive the matching placebo.

    Other: Placebo

Interventions

  • DrugOJR520

    Participants will receive OJR520 in different dose levels.

  • OtherPlacebo

    Participants will receive OJR520 matching placebo.

06

What researchers measure

Primary outcomes

  1. Number of participants with Adverse events (AEs) and Serious Adverse events (SAEs)

    Incidence and severity of AEs and SAEs by treatment group, including changes in vital signs, electrocardiograms (ECGs) and laboratory results qualifying and reported as AEs.

    Time frame: From Day 1 (Part A) until Day 71 (Part C)

Secondary outcomes

  1. Maximum Observed Blood Concentrations (Cmax)

    Cmax is the maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration (mass x volume-1).

    Time frame: From pre-dose Day 1 (Part A) until Day 71 (Part C)

  2. Time to reach maximum plasma concentration (Tmax)

    Tmax is the time to reach maximum (peak) drug concentration after single-dose administration (time).

    Time frame: From pre-dose Day 1 (Part A) until Day 71 (Part C)

  3. Area under plasma concentration-time curve (AUClast)

    AUClast is the area under the plasma concentration-time curve from time zero to the time of last quantifiable concentration (tlast).

    Time frame: From pre-dose Day 1 (Part A) until Day 71 (Part C)

  4. Area under the plasma concentration-time curve (AUC[0-inf])

    The AUC\[0-inf\] from time zero extrapolated to infinity (mass x time x volume-1).

    Time frame: From pre-dose Day 1 (Part A) until Day 71 (Part C)

  5. Terminal elimination half-life (T1/2)

    T1/2 is the elimination half-life associated with the terminal slope.

    Time frame: From pre-dose Day 1 (Part A) until Day 71 (Part C)

  6. Apparent plasma clearance (CL/F)

    CL/F is the apparent total body clearance of drug from plasma following extravascular administration.

    Time frame: From pre-dose Day 1 (Part A) until Day 71 (Part C)

  7. Apparent volume of distribution during terminal elimination phase (Vz/F)

    Vz/F is the apparent volume of distribution during terminal elimination phase following extravascular administration.

    Time frame: From pre-dose Day 1 (Part A) until Day 71 (Part C)

  8. Drug accumulation ratio (Racc)

    The ratio of accumulation of drug between the first and last dose, only for MAD part of the study.

    Time frame: Part C: From pre-dose Day 1 until Day 71

  9. Area under plasma concentration-time curve (AUCtau)

    The AUC calculated to the end of a dosing interval (tau) (amount x time x volume-1) only for MAD part of the study.

    Time frame: Part C: From pre-dose Day 1 until Day 71

07

Study locations

2 of 2 sites recruiting
  • Quotient Sciences Sea View
    Miami, Florida 33126, United States
    Recruiting
  • Novartis Investigative Site
    Berlin, 10117, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jan 2028, 26 months after the start.

Of 77 industry-sponsored phase 1 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's planned 26 months is above that.

Counting every sponsor, half of 109 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Nov 19, 2025
StartActual
Nov 20, 2025
Primary completionEst.
Jan 21, 2028
CompletionEst.
Jan 21, 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07235059
Responsible party
Sponsor
First posted
Nov 19, 2025
Start date
Nov 20, 2025
Primary completion
Jan 21, 2028 (estimated)
Completion
Jan 21, 2028 (estimated)
Last update
Nov 10, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
1-888-669-6682
Novartis Pharmaceuticals
Contact
+41613241111

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion